Last reviewed · How we verify
Chinese traditional medicine XH1
Chinese traditional medicine XH1 is a Small molecule drug developed by Haining Health-Coming Biotech Co., Ltd.. It is currently in Phase 2 development.
At a glance
| Generic name | Chinese traditional medicine XH1 |
|---|---|
| Sponsor | Haining Health-Coming Biotech Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Chinese traditional medicine XH1 CI brief — competitive landscape report
- Chinese traditional medicine XH1 updates RSS · CI watch RSS
- Haining Health-Coming Biotech Co., Ltd. portfolio CI
Frequently asked questions about Chinese traditional medicine XH1
What is Chinese traditional medicine XH1?
Chinese traditional medicine XH1 is a Small molecule drug developed by Haining Health-Coming Biotech Co., Ltd..
Who makes Chinese traditional medicine XH1?
Chinese traditional medicine XH1 is developed by Haining Health-Coming Biotech Co., Ltd. (see full Haining Health-Coming Biotech Co., Ltd. pipeline at /company/haining-health-coming-biotech-co-ltd).
What development phase is Chinese traditional medicine XH1 in?
Chinese traditional medicine XH1 is in Phase 2.